XBiotech (NASDAQ: XBIT)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.180 | ||||||
REV | 500.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of XBiotech (NASDAQ: XBIT) through any online brokerage.
Other companies in XBiotech’s space includes: Macrogenics (NASDAQ:MGNX), Graphite Bio (NASDAQ:GRPH), Jounce Therapeutics (NASDAQ:JNCE), Inozyme Pharma (NASDAQ:INZY) and Gritstone Bio (NASDAQ:GRTS).
The latest price target for XBiotech (NASDAQ: XBIT) was reported by Piper Sandler on Tuesday, April 7, 2020. The analyst firm set a price target for 18.00 expecting XBIT to rise to within 12 months (a possible 201.00% upside). 0 analyst firms have reported ratings in the last year.
The stock price for XBiotech (NASDAQ: XBIT) is $5.98 last updated Today at July 6, 2022, 4:21 PM UTC.
There are no upcoming dividends for XBiotech.
XBiotech’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for XBiotech.
XBiotech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.